Cameron Carl Foster, M.D. for UC Davis Health

Cameron Carl Foster, M.D.

Cameron Carl Foster, M.D.

Professor, Department of Radiology, Division of Nuclear Medicine

Cameron Carl Foster is not currently accepting new patients. For assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Nuclear Medicine

Department

Radiology

Locations and Contact

Lawrence J. Ellison Ambulatory Care Center

Radiology
4860 Y St.
Sacramento, CA 95817

Get Directions

UC Davis Medical Group - Folsom

UC Davis Medical Group - Folsom
271 Turn Pike Dr.
Folsom, CA 95630

Get Directions

Additional Numbers

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Foster is a Nuclear Medicine physician practicing a wide variety of both diagnostic imaging and therapeutic interventions. He has particular clinical interest in advanced applications of both clinical and research Theranostic agents.

Research/Academic Interests

Dr. Foster focuses on collaborative research for a wide array of molecular imaging and therapeutic agents including the development of new targeted cancer therapies.

Division

Nuclear Medicine

Center/Program Affiliation

UC Davis Medical Group

Undergraduate School

B.S., UC Davis, Davis CA 1999

Medical School

M.D., UC Davis School of Medicine, Sacramento CA 2003

Internship

Surgery, UC Davis, Sacramento CA 2003-2004

Residency

Nuclear Medicine, UC Davis, Sacramento CA 2004-2005

Residency

Chief Resident, Nuclear Medicine, UC Davis, Sacramento CA 2005-2006

Sacramento Magazine Top Doctor in Nuclear Medicine, 2019, 2021

Patient Safety Innovation Award for implementation of Lutathera treatment program, UC Davis Health, 2020

Excellence in Professionalism - UC Davis Health System, Department of Radiology, 2005

Costa GCA, Spencer BA, Omidvari N, Foster C, Rusnak M, Hunt H, Caudle DT, Pillai R, Vu C, Roncali E. Radioembolization Dosimetry with Total-Body 90Y PET. J Nucl Med. 2021 Nov 18:jnumed.121.263145. doi:10.2967/jnumed.121.263145. Epub ahead of print. PMID:34795015.

Foster CC, Davis RA, Hausner SH, Sutcliffe JL. αvβ6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection. J Nucl Med. 2020 Dec;61(12):1717-1719. doi:10.2967/jnumed.120.255364. Epub 2020 Sep 18. PMID:32948681.

Zuo Y, Badawi RD, Foster CC, Smith T, López JE, Wang G. Multiparametric Cardiac 18F-FDG PET in Humans: Kinetic Model Selection and Identifiability Analysis. IEEE Trans Radiat Plasma Med Sci. 2020 Nov;4(6):759-767. doi:10.1109/trpms.2020.3031274. Epub 2020 Oct 15. PMID:33778234.

Roncali E, Taebi A, Foster C, Vu CT. Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation. Ann Biomed Eng. 2020 May;48(5):1499-1510. doi:10.1007/s10439-020-02469-1. Epub 2020 Jan 31. PMID:32006268.

Hausner SH, Bold RJ, Cheuy LY, Chew HK, Daly ME, Davis RA, Foster CC, Kim EJ, Sutcliffe JL. Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma. Clin Cancer Res. 2019 Feb 15;25(4):1206-1215. doi:10.1158/1078-0432.CCR-18-2665. Epub 2018 Nov 6. PMID:30401687.

Zhou C, Foster B, Hagge R, Foster C, Boutin R, Chaudhari A. Prognostic value and multivariate analysis of body composition measures on 18F-FDG PET/CT imaging in patients with esophageal adenocarcinoma. J Nuclear Med. 2017;58(suppplement 1): 492.

Kuo J, Foster C, Shelton D. Particle disease on fluoride-18 (NaF) PET/CT imaging. J Radiol Case Rep. 2011;5(5):24-30. doi:10.3941/jrcr.v5i5.697. Epub 2011 May 1. PMID:22470793.

Kuo J, Foster CC, Shelton DK. The UCD experience with classic gastric emptying scintigraphy-systematic review and meta-analysis. J Biomed Graph Comput. 2011;1:10-23.

Lin FI, Foster CC, Hagge RJ, Shelton DK. Extensive FDG uptake in accessory muscles of respiration in a patient with shortness of breath. Clin Nucl Med. 2009 Jul;34(7):428-30. doi:10.1097/RLU.0b013e3181a7d1a9. PMID:19542946.

Lee BE, Redwine J, Foster C, Abella E, Lown T, Lau D, Follette D. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovasc Surg. 2008 Mar;135(3):615-9. doi:10.1016/j.jtcvs.2007.09.029. Epub 2008 Jan 11. PMID:18329480.